Association	O
of	O
Autoimmune	B:C0393639
Encephalitis	I:C0393639
With	O
Combined	O
Immune	O
Checkpoint	I:C1254351
Inhibitor	I:C1254351
Treatment	O
for	O
Metastatic	O
Cancer	I:C0027627
Paraneoplastic	O
encephalitides	I:C0338430
usually	O
precede	O
a	O
diagnosis	O
of	I:C0920688
cancer	I:C0920688
and	O
are	O
often	O
refractory	O
to	O
immunosuppressive	O
therapy	I:C0021079
.	O

Association	O
of	O
Autoimmune	O
Encephalitis	I:C0393639
With	O
Combined	O
Immune	B:C1254351
Checkpoint	I:C1254351
Inhibitor	I:C1254351
Treatment	O
for	O
Metastatic	O
Cancer	I:C0027627
Paraneoplastic	O
encephalitides	I:C0338430
usually	O
precede	O
a	O
diagnosis	O
of	I:C0920688
cancer	I:C0920688
and	O
are	O
often	O
refractory	O
to	O
immunosuppressive	O
therapy	I:C0021079
.	O

Association	O
of	O
Autoimmune	O
Encephalitis	I:C0393639
With	O
Combined	O
Immune	O
Checkpoint	I:C1254351
Inhibitor	I:C1254351
Treatment	O
for	O
Metastatic	B:C0027627
Cancer	I:C0027627
Paraneoplastic	O
encephalitides	I:C0338430
usually	O
precede	O
a	O
diagnosis	O
of	I:C0920688
cancer	I:C0920688
and	O
are	O
often	O
refractory	O
to	O
immunosuppressive	O
therapy	I:C0021079
.	O

Association	O
of	O
Autoimmune	O
Encephalitis	I:C0393639
With	O
Combined	O
Immune	O
Checkpoint	I:C1254351
Inhibitor	I:C1254351
Treatment	O
for	O
Metastatic	O
Cancer	I:C0027627
Paraneoplastic	B:C0338430
encephalitides	I:C0338430
usually	O
precede	O
a	O
diagnosis	O
of	I:C0920688
cancer	I:C0920688
and	O
are	O
often	O
refractory	O
to	O
immunosuppressive	O
therapy	I:C0021079
.	O

Association	O
of	O
Autoimmune	O
Encephalitis	I:C0393639
With	O
Combined	O
Immune	O
Checkpoint	I:C1254351
Inhibitor	I:C1254351
Treatment	O
for	O
Metastatic	O
Cancer	I:C0027627
Paraneoplastic	O
encephalitides	I:C0338430
usually	O
precede	O
a	O
diagnosis	B:C0920688
of	I:C0920688
cancer	I:C0920688
and	O
are	O
often	O
refractory	O
to	O
immunosuppressive	O
therapy	I:C0021079
.	O

Association	O
of	O
Autoimmune	O
Encephalitis	I:C0393639
With	O
Combined	O
Immune	O
Checkpoint	I:C1254351
Inhibitor	I:C1254351
Treatment	O
for	O
Metastatic	O
Cancer	I:C0027627
Paraneoplastic	O
encephalitides	I:C0338430
usually	O
precede	O
a	O
diagnosis	O
of	I:C0920688
cancer	I:C0920688
and	O
are	O
often	O
refractory	O
to	O
immunosuppressive	B:C0021079
therapy	I:C0021079
.	O

Conversely	O
,	O
autoimmune	B:C0393639
encephalitides	I:C0393639
are	O
reversible	O
conditions	O
that	O
can	O
occur	O
in	O
the	O
presence	O
or	O
absence	O
of	O
cancer	O
.	O

Conversely	O
,	O
autoimmune	O
encephalitides	I:C0393639
are	O
reversible	O
conditions	O
that	O
can	O
occur	O
in	O
the	O
presence	B:C0150312
or	O
absence	O
of	O
cancer	O
.	O

Conversely	O
,	O
autoimmune	O
encephalitides	I:C0393639
are	O
reversible	O
conditions	O
that	O
can	O
occur	O
in	O
the	O
presence	O
or	O
absence	O
of	O
cancer	B:C0006826
.	O

To	O
report	O
the	O
induction	O
of	O
autoimmune	B:C0393639
encephalitis	I:C0393639
in	O
2	O
patients	O
after	O
treatment	O
of	O
metastatic	O
cancer	I:C0027627
with	O
a	O
combination	O
of	O
the	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	O
and	O
ipilimumab	O
.	O

To	O
report	O
the	O
induction	O
of	O
autoimmune	O
encephalitis	I:C0393639
in	O
2	O
patients	O
after	O
treatment	O
of	O
metastatic	B:C0027627
cancer	I:C0027627
with	O
a	O
combination	O
of	O
the	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	O
and	O
ipilimumab	O
.	O

To	O
report	O
the	O
induction	O
of	O
autoimmune	O
encephalitis	I:C0393639
in	O
2	O
patients	O
after	O
treatment	O
of	O
metastatic	O
cancer	I:C0027627
with	O
a	O
combination	O
of	O
the	O
immune	B:C1254351
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	O
and	O
ipilimumab	O
.	O

To	O
report	O
the	O
induction	O
of	O
autoimmune	O
encephalitis	I:C0393639
in	O
2	O
patients	O
after	O
treatment	O
of	O
metastatic	O
cancer	I:C0027627
with	O
a	O
combination	O
of	O
the	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	B:C3657270
and	O
ipilimumab	O
.	O

To	O
report	O
the	O
induction	O
of	O
autoimmune	O
encephalitis	I:C0393639
in	O
2	O
patients	O
after	O
treatment	O
of	O
metastatic	O
cancer	I:C0027627
with	O
a	O
combination	O
of	O
the	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	O
and	O
ipilimumab	B:C1367202
.	O

A	O
retrospective	B:C0035363
case	I:C0035363
study	I:C0035363
was	O
conducted	O
of	O
the	O
clinical	O
and	I:C1516615
management	I:C1516615
course	O
of	O
2	O
patients	O
with	O
progressive	O
,	O
treatment	O
-	O
refractory	O
metastatic	I:C0677936
cancer	I:C0677936
who	O
were	O
treated	O
with	I:C0332293
a	O
single	O
dose	O
each	O
(	O
concomitantly	O
)	O
of	O
the	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	O
,	O
1	O
mg/	O
kg	O
,	O
and	O
ipilimumab	O
,	O
3	O
mg	O
/	O
kg	O
.	O

A	O
retrospective	O
case	I:C0035363
study	I:C0035363
was	O
conducted	O
of	O
the	O
clinical	B:C1516615
and	I:C1516615
management	I:C1516615
course	O
of	O
2	O
patients	O
with	O
progressive	O
,	O
treatment	O
-	O
refractory	O
metastatic	I:C0677936
cancer	I:C0677936
who	O
were	O
treated	O
with	I:C0332293
a	O
single	O
dose	O
each	O
(	O
concomitantly	O
)	O
of	O
the	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	O
,	O
1	O
mg/	O
kg	O
,	O
and	O
ipilimumab	O
,	O
3	O
mg	O
/	O
kg	O
.	O

A	O
retrospective	O
case	I:C0035363
study	I:C0035363
was	O
conducted	O
of	O
the	O
clinical	O
and	I:C1516615
management	I:C1516615
course	O
of	O
2	O
patients	O
with	O
progressive	O
,	O
treatment	O
-	O
refractory	B:C0677936
metastatic	I:C0677936
cancer	I:C0677936
who	O
were	O
treated	O
with	I:C0332293
a	O
single	O
dose	O
each	O
(	O
concomitantly	O
)	O
of	O
the	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	O
,	O
1	O
mg/	O
kg	O
,	O
and	O
ipilimumab	O
,	O
3	O
mg	O
/	O
kg	O
.	O

A	O
retrospective	O
case	I:C0035363
study	I:C0035363
was	O
conducted	O
of	O
the	O
clinical	O
and	I:C1516615
management	I:C1516615
course	O
of	O
2	O
patients	O
with	O
progressive	O
,	O
treatment	O
-	O
refractory	O
metastatic	I:C0677936
cancer	I:C0677936
who	O
were	O
treated	B:C0332293
with	I:C0332293
a	O
single	O
dose	O
each	O
(	O
concomitantly	O
)	O
of	O
the	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	O
,	O
1	O
mg/	O
kg	O
,	O
and	O
ipilimumab	O
,	O
3	O
mg	O
/	O
kg	O
.	O

A	O
retrospective	O
case	I:C0035363
study	I:C0035363
was	O
conducted	O
of	O
the	O
clinical	O
and	I:C1516615
management	I:C1516615
course	O
of	O
2	O
patients	O
with	O
progressive	O
,	O
treatment	O
-	O
refractory	O
metastatic	I:C0677936
cancer	I:C0677936
who	O
were	O
treated	O
with	I:C0332293
a	O
single	O
dose	O
each	O
(	O
concomitantly	O
)	O
of	O
the	O
immune	B:C1254351
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	O
,	O
1	O
mg/	O
kg	O
,	O
and	O
ipilimumab	O
,	O
3	O
mg	O
/	O
kg	O
.	O

A	O
retrospective	O
case	I:C0035363
study	I:C0035363
was	O
conducted	O
of	O
the	O
clinical	O
and	I:C1516615
management	I:C1516615
course	O
of	O
2	O
patients	O
with	O
progressive	O
,	O
treatment	O
-	O
refractory	O
metastatic	I:C0677936
cancer	I:C0677936
who	O
were	O
treated	O
with	I:C0332293
a	O
single	O
dose	O
each	O
(	O
concomitantly	O
)	O
of	O
the	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	B:C3657270
,	O
1	O
mg/	O
kg	O
,	O
and	O
ipilimumab	O
,	O
3	O
mg	O
/	O
kg	O
.	O

A	O
retrospective	O
case	I:C0035363
study	I:C0035363
was	O
conducted	O
of	O
the	O
clinical	O
and	I:C1516615
management	I:C1516615
course	O
of	O
2	O
patients	O
with	O
progressive	O
,	O
treatment	O
-	O
refractory	O
metastatic	I:C0677936
cancer	I:C0677936
who	O
were	O
treated	O
with	I:C0332293
a	O
single	O
dose	O
each	O
(	O
concomitantly	O
)	O
of	O
the	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
nivolumab	O
,	O
1	O
mg/	O
kg	O
,	O
and	O
ipilimumab	B:C1367202
,	O
3	O
mg	O
/	O
kg	O
.	O

Nivolumab	B:C3657270
and	O
ipilimumab	O
.	O

Nivolumab	O
and	O
ipilimumab	B:C1367202
.	O

The	O
clinical	B:C4055223
response	I:C4055223
to	O
immunosuppressive	O
therapy	I:C0021079
in	O
suspected	O
autoimmune	O
encephalitis	I:C0393639
in	O
the	O
setting	O
of	O
immune	O
checkpoint	I:C1254351
inhibitor	I:C1254351
use	O
.	O

The	O
clinical	O
response	I:C4055223
to	O
immunosuppressive	B:C0021079
therapy	I:C0021079
in	O
suspected	O
autoimmune	O
encephalitis	I:C0393639
in	O
the	O
setting	O
of	O
immune	O
checkpoint	I:C1254351
inhibitor	I:C1254351
use	O
.	O

The	O
clinical	O
response	I:C4055223
to	O
immunosuppressive	O
therapy	I:C0021079
in	O
suspected	O
autoimmune	B:C0393639
encephalitis	I:C0393639
in	O
the	O
setting	O
of	O
immune	O
checkpoint	I:C1254351
inhibitor	I:C1254351
use	O
.	O

The	O
clinical	O
response	I:C4055223
to	O
immunosuppressive	O
therapy	I:C0021079
in	O
suspected	O
autoimmune	O
encephalitis	I:C0393639
in	O
the	O
setting	O
of	O
immune	B:C1254351
checkpoint	I:C1254351
inhibitor	I:C1254351
use	O
.	O

Autoantibody	B:C1272321
testing	I:C1272321
confirmed	O
identification	O
of	O
anti-N-	O
methyl	I:C3203613
-	I:C3203613
D-	I:C3203613
aspartate	I:C3203613
receptor	I:C3203613
antibodies	I:C3203613
in	O
the	O
cerebrospinal	O
fluid	I:C0007806
of	O
1	O
patient	O
.	O

Autoantibody	O
testing	I:C1272321
confirmed	B:C0750484
identification	O
of	O
anti-N-	O
methyl	I:C3203613
-	I:C3203613
D-	I:C3203613
aspartate	I:C3203613
receptor	I:C3203613
antibodies	I:C3203613
in	O
the	O
cerebrospinal	O
fluid	I:C0007806
of	O
1	O
patient	O
.	O

Autoantibody	O
testing	I:C1272321
confirmed	O
identification	O
of	O
anti-N-	B:C3203613
methyl	I:C3203613
-	I:C3203613
D-	I:C3203613
aspartate	I:C3203613
receptor	I:C3203613
antibodies	I:C3203613
in	O
the	O
cerebrospinal	O
fluid	I:C0007806
of	O
1	O
patient	O
.	O

Autoantibody	O
testing	I:C1272321
confirmed	O
identification	O
of	O
anti-N-	O
methyl	I:C3203613
-	I:C3203613
D-	I:C3203613
aspartate	I:C3203613
receptor	I:C3203613
antibodies	I:C3203613
in	O
the	O
cerebrospinal	B:C0007806
fluid	I:C0007806
of	O
1	O
patient	O
.	O

Withdrawal	O
of	O
immune	B:C1254351
checkpoint	I:C1254351
inhibitors	I:C1254351
and	O
initiation	O
of	O
immunosuppressive	O
therapy	I:C0021079
,	O
consisting	O
of	O
intravenous	O
methylprednisolone	O
sodium	O
succinate	O
equivalent	O
to	O
1000	O
mg	O
of	O
methylprednisolone	O
for	O
5	O
days	O
,	O
0.4	O
mg/kg/d	O
of	O
intravenous	O
immunoglobulin	I:C0085297
for	O
5	O
days	O
,	O
and	O
2	O
doses	O
of	O
rituximab	O
,	O
1000	O
mg	O
,	O
in	O
1	O
patient	O
and	O
oral	O
prednisone	O
,	O
60	O
mg/d	O
,	O
in	O
the	O
other	O
patient	O
,	O
resulted	O
in	O
improved	O
neurologic	O
symptoms	I:C0235031
.	O

Withdrawal	O
of	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
and	O
initiation	O
of	O
immunosuppressive	B:C0021079
therapy	I:C0021079
,	O
consisting	O
of	O
intravenous	O
methylprednisolone	O
sodium	O
succinate	O
equivalent	O
to	O
1000	O
mg	O
of	O
methylprednisolone	O
for	O
5	O
days	O
,	O
0.4	O
mg/kg/d	O
of	O
intravenous	O
immunoglobulin	I:C0085297
for	O
5	O
days	O
,	O
and	O
2	O
doses	O
of	O
rituximab	O
,	O
1000	O
mg	O
,	O
in	O
1	O
patient	O
and	O
oral	O
prednisone	O
,	O
60	O
mg/d	O
,	O
in	O
the	O
other	O
patient	O
,	O
resulted	O
in	O
improved	O
neurologic	O
symptoms	I:C0235031
.	O

Withdrawal	O
of	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
and	O
initiation	O
of	O
immunosuppressive	O
therapy	I:C0021079
,	O
consisting	O
of	O
intravenous	O
methylprednisolone	O
sodium	O
succinate	O
equivalent	O
to	O
1000	O
mg	O
of	O
methylprednisolone	O
for	O
5	O
days	O
,	O
0.4	O
mg/kg/d	O
of	O
intravenous	B:C0085297
immunoglobulin	I:C0085297
for	O
5	O
days	O
,	O
and	O
2	O
doses	O
of	O
rituximab	O
,	O
1000	O
mg	O
,	O
in	O
1	O
patient	O
and	O
oral	O
prednisone	O
,	O
60	O
mg/d	O
,	O
in	O
the	O
other	O
patient	O
,	O
resulted	O
in	O
improved	O
neurologic	O
symptoms	I:C0235031
.	O

Withdrawal	O
of	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
and	O
initiation	O
of	O
immunosuppressive	O
therapy	I:C0021079
,	O
consisting	O
of	O
intravenous	O
methylprednisolone	O
sodium	O
succinate	O
equivalent	O
to	O
1000	O
mg	O
of	O
methylprednisolone	O
for	O
5	O
days	O
,	O
0.4	O
mg/kg/d	O
of	O
intravenous	O
immunoglobulin	I:C0085297
for	O
5	O
days	O
,	O
and	O
2	O
doses	O
of	O
rituximab	B:C0393022
,	O
1000	O
mg	O
,	O
in	O
1	O
patient	O
and	O
oral	O
prednisone	O
,	O
60	O
mg/d	O
,	O
in	O
the	O
other	O
patient	O
,	O
resulted	O
in	O
improved	O
neurologic	O
symptoms	I:C0235031
.	O

Withdrawal	O
of	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
and	O
initiation	O
of	O
immunosuppressive	O
therapy	I:C0021079
,	O
consisting	O
of	O
intravenous	O
methylprednisolone	O
sodium	O
succinate	O
equivalent	O
to	O
1000	O
mg	O
of	O
methylprednisolone	O
for	O
5	O
days	O
,	O
0.4	O
mg/kg/d	O
of	O
intravenous	O
immunoglobulin	I:C0085297
for	O
5	O
days	O
,	O
and	O
2	O
doses	O
of	O
rituximab	O
,	O
1000	O
mg	O
,	O
in	O
1	O
patient	O
and	O
oral	O
prednisone	O
,	O
60	O
mg/d	O
,	O
in	O
the	O
other	O
patient	O
,	O
resulted	O
in	O
improved	B:C0184511
neurologic	O
symptoms	I:C0235031
.	O

Withdrawal	O
of	O
immune	O
checkpoint	I:C1254351
inhibitors	I:C1254351
and	O
initiation	O
of	O
immunosuppressive	O
therapy	I:C0021079
,	O
consisting	O
of	O
intravenous	O
methylprednisolone	O
sodium	O
succinate	O
equivalent	O
to	O
1000	O
mg	O
of	O
methylprednisolone	O
for	O
5	O
days	O
,	O
0.4	O
mg/kg/d	O
of	O
intravenous	O
immunoglobulin	I:C0085297
for	O
5	O
days	O
,	O
and	O
2	O
doses	O
of	O
rituximab	O
,	O
1000	O
mg	O
,	O
in	O
1	O
patient	O
and	O
oral	O
prednisone	O
,	O
60	O
mg/d	O
,	O
in	O
the	O
other	O
patient	O
,	O
resulted	O
in	O
improved	O
neurologic	B:C0235031
symptoms	I:C0235031
.	O

Immune	B:C2255931
checkpoint	I:C2255931
inhibition	I:C2255931
may	O
favor	O
the	O
development	O
of	O
immune	O
responses	I:C0301872
against	O
neuronal	O
antigens	O
,	O
leading	O
to	O
autoimmune	O
encephalitis	I:C0393639
.	O

Immune	O
checkpoint	I:C2255931
inhibition	I:C2255931
may	O
favor	O
the	O
development	O
of	O
immune	B:C0301872
responses	I:C0301872
against	O
neuronal	O
antigens	O
,	O
leading	O
to	O
autoimmune	O
encephalitis	I:C0393639
.	O

Immune	O
checkpoint	I:C2255931
inhibition	I:C2255931
may	O
favor	O
the	O
development	O
of	O
immune	O
responses	I:C0301872
against	O
neuronal	O
antigens	O
,	O
leading	O
to	O
autoimmune	B:C0393639
encephalitis	I:C0393639
.	O

Early	O
recognition	O
and	O
treatment	O
of	O
autoimmune	B:C0393639
encephalitis	I:C0393639
in	O
patients	O
receiving	O
immune	O
checkpoint	I:C0021079
blockade	I:C0021079
therapy	I:C0021079
will	O
likely	O
be	O
essential	O
for	O
maximizing	O
clinical	O
recovery	O
and	O
minimizing	O
the	O
effect	O
of	O
drug	O
-	O
related	O
toxic	O
effects	O
.	O

Early	O
recognition	O
and	O
treatment	O
of	O
autoimmune	O
encephalitis	I:C0393639
in	O
patients	O
receiving	O
immune	B:C0021079
checkpoint	I:C0021079
blockade	I:C0021079
therapy	I:C0021079
will	O
likely	O
be	O
essential	O
for	O
maximizing	O
clinical	O
recovery	O
and	O
minimizing	O
the	O
effect	O
of	O
drug	O
-	O
related	O
toxic	O
effects	O
.	O

The	O
mechanisms	O
by	O
which	O
immune	B:C2255931
checkpoint	I:C2255931
inhibition	I:C2255931
may	O
contribute	O
to	O
autoimmune	O
encephalitis	I:C0393639
require	O
further	O
study	O
.	O

The	O
mechanisms	O
by	O
which	O
immune	O
checkpoint	I:C2255931
inhibition	I:C2255931
may	O
contribute	O
to	O
autoimmune	B:C0393639
encephalitis	I:C0393639
require	O
further	O
study	O
.	O

